NCT03975231View on ClinicalTrials.gov

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 14, 2020

Primary Completion Date

October 4, 2025

Study Completion Date

October 4, 2025

Conditions
BRAF NP_004324.2:p.V600EBRAF V600K Mutation PresentThyroid Gland Anaplastic Carcinoma
Interventions
DRUG

Dabrafenib

Given PO

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

DRUG

Trametinib

Given PO

Trial Locations (3)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

77030

RECRUITING

Univ of Texas-M.D. Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT03975231 - Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer | Biotech Hunter | Biotech Hunter